AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

AstraZeneca (NASDAQ:AZN) and partner Daiichi Sanyko (OTCPK:DSKYF)(OTCPK:DSNKY) said the FDA has accepted their application ...

The fight to lower prescription drug prices is hitting African Americans especially hard. A recent report by Patients ...

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, ...

The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...

Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...